The USFDA recently approved ranibizumab-eqrn, a biosimilar of ranibizumab injection. It belongs to the anti-vascular endothelial growth factor (VEGF) class of biologics that are useful for maintaining or improving vision in retinal patients. Drug details This approval is based on a comprehensive COLUMBUS-AMD study conducted to test the efficacy and safety of this biosimilar.
Do you think this biosimilar will be a useful alternative for retinal problems? Source: USFDA, Ophthalmology
